Further, a study of over 2500 cases of different types of cancers stratified in metastatic versus primary tumors revealed that the CD36 gene was frequently amplified in metastatic groups and, similarly, poor survival rates correlate with CD36 high-copy numbers [137]. This evidence concerns the gene CD36 and cancer.